Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.
Tapinarof Cream 1% Rapidly Improves Mild to Severe Plaque Psoriasis
October 23rd 2023Patients with plaque psoriasis, including in intertriginous areas and genitalia, experienced rapid improvement when treated with tapinarof cream 1%, offering an effective and well-tolerated nonsteroidal option for this condition.
Read More
Tildrakizumab Significantly Improves Work Productivity in Moderate to Severe Plaque Psoriasis
October 22nd 2023Tildrakizumab significantly improved work productivity and reduced work activity impairment in patients with moderate to severe plaque psoriasis, highlighting this treatment's quality of life benefits.
Read More
Linda Stein Gold, MD: Nonsteroidal Topical Treatment for Psoriasis, Atopic Dermatitis
October 21st 2023Linda Stein Gold, MD, discusses the notable transition in topical therapies for both psoriasis and atopic dermatitis, with the introduction of effective FDA-approved nonsteroidal treatments.
Read More
What Factors Should Clinicians Consider When Treating Psoriasis in Skin of Color?
October 20th 2023Mona Shahriari, MD, and Andrew F Alexis, MD, MPH, discussed the multifaceted considerations dermatologists should weigh when treating patients with skin of color diagnosed with plaque psoriasis.
Read More
No Differences in Safety, Immunogenicity Observed in Patients Switching to Biosimilar
October 15th 2023Results of a recent systematic review demonstrated no difference in the immunogenicity rates and safety profiles in patients who switched to a biosimilar and those who continued to receive the reference product.
Read More
Prophylaxis Increases Risk of Adverse Events in Patients Initiating Allopurinol for Gout
October 10th 2023In patients initiating allopurinal, adverse events were more common in those receiving concomitant colchicine or nonsteroidal anti-inflammatory drugs compared to those without prophylaxis.
Read More